15 19

Cited 0 times in

Similar Clinical Outcomes of Early and Late Anti-TNF Initiation for Ulcerative Colitis: A Nationwide Population-Based Study

DC FieldValueLanguage
dc.contributor.author천재희-
dc.contributor.author박소희-
dc.date.accessioned2020-09-28T11:30:41Z-
dc.date.available2020-09-28T11:30:41Z-
dc.date.issued2020-05-
dc.identifier.issn0513-5796-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/179213-
dc.description.abstractPurpose: The optimal timing of anti-tumor necrosis factor (anti-TNF) initiation in patients with ulcerative colitis (UC) remains unclear. Very little is known about the clinical outcomes after the early versus late initiation of anti-TNF therapy, especially in Asian UC patients. Here we aimed to assess whether earlier anti-TNF treatment initiation results in favorable clinical outcomes in Korean UC patients. Materials and methods: Using the Korean National Health Insurance claims database, we studied patients who were diagnosed with UC and received anti-TNF therapy for more than 6 months between 2010 and 2016. Using a Cox proportional hazard model, clinical outcomes including colectomy, UC-related emergency room (ER) visits, UC-related hospitalizations, and the need for corticosteroids were compared between early (≤2 years of diagnosis) and late (>2 years of diagnosis) initiators of anti-TNF therapy. Results: Among 17167 UC patients, 698 patients who received anti-TNF therapy for more than 6 months were included (420 infliximab, 242 adalimumab, and 36 golimumab). Of the 698 patients, 299 (42.8%) initiated anti-TNF therapy within 2 years of diagnosis. There were no significant differences in the risk of colectomy [adjusted hazard ratio (aHR), 0.41; 95% confidence interval (CI), 0.04-3.90], ER visits (aHR, 0.98; 95% CI, 0.50-1.92), hospitalization (aHR, 0.76; 95% CI, 0.57-1.01), and corticosteroid use (aHR, 1.04; 95% CI, 0.71-1.50) between early and late initiators of anti-TNF therapy. Conclusion: Patients receiving early anti-TNF therapy had similar clinical outcomes to those of late initiators, suggesting that early anti-TNF therapy initiation offers little benefit in patients with UC.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherYonsei University-
dc.relation.isPartOfYONSEI MEDICAL JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAdalimumab / therapeutic use-
dc.subject.MESHAdult-
dc.subject.MESHAntibodies, Monoclonal / therapeutic use-
dc.subject.MESHColitis, Ulcerative / drug therapy*-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHInfliximab / therapeutic use-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHMale-
dc.subject.MESHProportional Hazards Models-
dc.subject.MESHRegression Analysis-
dc.subject.MESHTime Factors-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHTumor Necrosis Factor-alpha / antagonists & inhibitors*-
dc.titleSimilar Clinical Outcomes of Early and Late Anti-TNF Initiation for Ulcerative Colitis: A Nationwide Population-Based Study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorMinkyung Han-
dc.contributor.googleauthorYoon Suk Jung-
dc.contributor.googleauthorJae Hee Cheon-
dc.contributor.googleauthorSohee Park-
dc.identifier.doi10.3349/ymj.2020.61.5.382-
dc.contributor.localIdA04030-
dc.contributor.localIdA01531-
dc.contributor.localIdA01531-
dc.relation.journalcodeJ02813-
dc.identifier.eissn1976-2437-
dc.identifier.pmid32390361-
dc.subject.keywordUlcerative colitis-
dc.subject.keywordanti-TNF-
dc.subject.keywordclinical outcome-
dc.subject.keywordearly use-
dc.contributor.alternativeNameCheon, Jae Hee-
dc.contributor.affiliatedAuthor천재희-
dc.contributor.affiliatedAuthor박소희-
dc.contributor.affiliatedAuthor박소희-
dc.citation.volume61-
dc.citation.number5-
dc.citation.startPage382-
dc.citation.endPage390-
dc.identifier.bibliographicCitationYONSEI MEDICAL JOURNAL, Vol.61(5) : 382-390, 2020-05-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
4. Graduate School of Public Health (보건대학원) > Graduate School of Public Health (보건대학원) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.